Cross-regulation between type I and type IINKT cells in regulating tumor immunity: A new immunoregulatory axis

被引:158
作者
Ambrosino, Elena
Terabe, Masaki
Halder, Ramesh C.
Peng, Judy
Takaku, Shun
Miyake, Sachiko
Yamamura, Takashi
Kumar, Vipin
Berzofsky, Jay A.
机构
[1] NCI, NIH, Vaccine Branch, Bethesda, MD 20892 USA
[2] Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA
[3] Natl Inst Neurosci, Tokyo, Japan
关键词
D O I
10.4049/jimmunol.179.8.5126
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Negative immunoregulation is a major barrier to successful cancer immunotherapy. The NKT cell is known to be one such regulator. In this study we explored the roles of and interaction between the classical type I NKT cell and the poorly understood type II NKT cell in the regulation of tumor immunity. Selective stimulation of type II NKT cells suppressed immunosurveillance, whereas stimulation of type I NKT cells protected against tumor growth even when responses were relatively skewed toward Th2 cytokines. When both were stimulated simultaneously, type II NKT cells appeared to suppress the activation in vitro and protective effect in vivo of type I NKT cells. In the absence of type I, suppression by type II NKT cells increased, suggesting that type I cells reduce the suppressive effect of type II NKT cells. Thus, in tumor immunity type I and type II NKT cells have opposite and counteractive roles and define a new immunoregulatory axis. Alteration of the balance between the protective type I and the suppressive type II NKT cell may be exploited for therapeutic intervention in cancer.
引用
收藏
页码:5126 / 5136
页数:11
相关论文
共 50 条
  • [1] Azuma T, 2003, CANCER RES, V63, P4516
  • [2] Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection
    Baron, JL
    Gardiner, L
    Nishimura, S
    Shinkai, K
    Locksley, R
    Ganem, D
    [J]. IMMUNITY, 2002, 16 (04) : 583 - 594
  • [3] Behar SM, 1999, J IMMUNOL, V162, P161
  • [4] Progress on new vaccine strategies for the immunotherapy and prevention of cancer
    Berzofsky, JA
    Terabe, M
    Oh, SK
    Belyakov, IM
    Ahlers, JD
    Janik, JE
    Morris, JC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (11) : 1515 - 1525
  • [5] Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells
    Bronte, V
    Apolloni, E
    Cabrelle, A
    Ronca, R
    Serafini, P
    Zamboni, P
    Restifo, NP
    Zanovello, P
    [J]. BLOOD, 2000, 96 (12) : 3838 - 3846
  • [6] CD1-RESTRICTED CD4(+) T-CELLS IN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II-DEFICIENT MICE
    CARDELL, S
    TANGRI, S
    CHAN, S
    KRONENBERG, M
    BENOIST, C
    MATHIS, D
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (04) : 993 - 1004
  • [7] Casares N, 2001, EUR J IMMUNOL, V31, P1780, DOI 10.1002/1521-4141(200106)31:6<1780::AID-IMMU1780>3.0.CO
  • [8] 2-I
  • [9] Suppression of collagen-induced arthritis by natural killer T cell activation with OCK a sphingosine-truncated analog of α-galactosylceramide
    Chiba, A
    Oki, S
    Miyamoto, K
    Hashimoto, H
    Yamamura, T
    Miyake, S
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (01): : 305 - 313
  • [10] Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments
    Chiu, YH
    Jayawardena, J
    Weiss, A
    Lee, D
    Park, SH
    Dautry-Varsat, A
    Bendelac, A
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (01) : 103 - 110